Myotonic dystrophy type 1 (DM1), the most common form of adult onset muscular dystrophy, is an incurable neuromuscular disorder. Its genetic origin is a triplet (CTG) repeat expansion in the 3'-untranslated region (UTR) of the dystrophia myotonica protein kinase (DMPK) gene. No treatment options exist to delay disease progression. Strong evidence supports a gain-of-function role for the expanded RNA transcript (rCUGexp) and it is considered the toxic agent that causes DM1. The rCUGexp sequesters important proteins, inhibiting their normal function. Chief among these proteins is muscleblind-like protein 1 (MBNL1), a key regulator of alternative splicing. Its sequestration leads to the mis-splicing of >100 pre-mRNAs and many of the symptoms of DM1. The overall goal of this proposal is to discover novel therapeutic approaches and to identify and develop agents that target dCTGexp to inhibit its transcription and rCUGexp, if formed, to liberate sequestered protein. These agents may serve ultimately as new lead therapeutic agents for DM1. Agents that function well in cell culture models will be assessed for their drug-like abilities (e.g., ADME-tox) and suitable leads will be tested in sophisticated animal models scoring both phenotypic improvements (e.g., cardiac function) and correlating this with target-based activity (levels of relevant spliced RNAs). The speci?c aims of the proposal are: (1) Discovery and Development of Small Molecules that Bind dCTGexp and rCUGexp, (2) Development of Self-Assembling Therapeutics Targeting dCTGexp and rCUGexp, (3) Polymer Approaches to Targeting dCTGexp and rCUGexp, and (4) Evaluation of Promising Agents in Cellular Assays and Drosophila and Mouse Models of DM1.

Public Health Relevance

. Relevance. Myotonic dystrophy (DM1) afflicts approximately 1 in 8000 adults and is characterized by progressive muscular weakness, cardiac defects, cataracts, and other neuromuscular problems. We propose to develop novel drug discovery approaches for DM1 that involve using small molecules to directly target the aberrantly expanded DNA and inhibit its conversion to the toxic RNA, and to target the toxic RNA to prevent important proteins from binding so that they may perform their normal functions. This approach may serve as a prototype for the treatment of other diseases caused by expanded DNA sequences and their toxic RNA products.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
1R01AR069645-01A1
Application #
9239005
Study Section
Synthetic and Biological Chemistry A Study Section (SBCA)
Program Officer
Cheever, Thomas
Project Start
2017-03-01
Project End
2022-01-31
Budget Start
2017-03-01
Budget End
2018-01-31
Support Year
1
Fiscal Year
2017
Total Cost
$475,337
Indirect Cost
$138,979
Name
University of Illinois Urbana-Champaign
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
041544081
City
Champaign
State
IL
Country
United States
Zip Code
61820